Article

Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma Patients

2021-08-31

Abstract excerpt

<title>Abstract</title> <p>BackgroundPancreatic ductal adenocarcinoma (PDAC) is highly aggressive and has poor prognosis. There are few biomarkers to inform treatment decisions, and collecting tumor samples for genomic or drug sensitivity testing is challenging.MethodsCirculating tumor cells (CTCs) were prepared from the liquid biopsies of PDAC patients. These cells were subsequently expanded <italic>ex vivo</ita...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8695fd9c-c7d5-53c4-be25-3621369d2d9e
DOI: 10.21203/rs.3.rs-845754/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma PatientsDOI 10.21203/rs.3.rs-845754/v1Read

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read

Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer.Semantic proximity Read

Pancreatic cancer organoids derived from EUS-guided fine needle aspiration specimens can be used to predict chemotherapy resistance.Semantic proximity Read

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read

Pancreatic adenocarcinoma human organoids share structural and genetic features with primary tumorsSemantic proximity Read

Mature tumoroids recapitulate clinically relevant drug response through extended 3D culture in PDACSemantic proximity Read

Establishing 3D Organoid Models from Patient-Derived Conditionally Reprogrammed Cells to Bridge Preclinical and Clinical Insights in Pancreatic CancerSemantic proximity Read

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read

Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancerSemantic proximity Read

Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoidsSemantic proximity Read

Optimized large-scale longitudinal biorepository of gastroesophageal adenocarcinoma patient-derived organoids: High-fidelity models for personalized treatment to overcome resistanceSemantic proximity Read

Patient-derived esophageal adenocarcinoma organ chip: a physiologically relevant platform for functional precision oncologySemantic proximity Read